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microangiopathy, Thrombotic thrombocytopenic purpuraThrombocytopenia affects 25–55% of intensive care unit
(ICU) patients [1]. The reasons for thrombocytopenia in
the ICU are numerous, including, among others, sepsis,
drugs, and the use of extracorporeal devices (Fig. 1) [1].
Some patients with thrombocytopenia also have micro-
angiopathic hemolytic anemia (MAHA), accompanied
by elevated serum lactate dehydrogenase levels and
schistocytes on the blood film [2, 3]. This combination
of thrombocytopenia and MAHA, in which thrombi
form in the microvasculature and schistocytes develop
from red cell destruction as they pass over these thrombi
[2], occurs in patients with disseminated intravascular
coagulation (DIC), but also in those with thrombotic
microangiopathies (TMAs), including thrombotic
thrombocytopenic purpura (TTP) and hemolytic uremic
syndrome (HUS).
DIC is relatively common, developing in 9–19% of
ICU patients, usually as a result of sepsis [4], with an
incidence of 18/100,000 in the overall population [2, 5].
By contrast, TTP and Shiga-toxin producing Escherichia
coli (STEC)-associated HUS have estimated incidences
of 6 and up to 29 cases per million, respectively, and
atypical HUS (aHUS) a prevalence of 0.2–0.4 cases per
million [6, 7], making these conditions far rarer than
DIC. Although TTP is described as a pentad of fever,
thrombocytopenia, MAHA, renal dysfunction, and
neurological impairment, often some of these features* Correspondence: jlvincent@intensive.org
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with HUS, which is most commonly characterized by
the triad of thrombocytopenia, MAHA, and renal dys-
function [3]. These clinical similarities of DIC, TTP, and
HUS are a major concern because they pose a risk of
misdiagnosis as intensivists are more likely to consider a
diagnosis of DIC than of the rarer TTP or HUS, thus
delaying potentially lifesaving treatment.
Several diagnostic algorithms for TMA have been pub-
lished [3, 8–10]. However, currently the only available
guidance specific to the ICU are the recently published
expert statements of Azoulay and colleagues [11]. This
publication provides an excellent guide for the differen-
tial diagnosis of TMAs but only briefly mentions DIC. A
concise diagnostic algorithm tailored to intensivists
would aid rapid differential diagnosis of TTP and HUS
from DIC, and enable early appropriate treatment.
A new algorithm to rapidly differentiate DIC from
TTP and HUS in the ICU
Given the importance of differentiating DIC from TTP
and HUS, we propose a concise algorithm based on exist-
ing guidance [3, 9, 11] and our own discussions which will
enable the intensivist to rapidly distinguish between these
entities (Fig. 1). MAHA, negative Coombs test, elevated
lactate dehydrogenase (LDH) levels, and organ dysfunc-
tion with thrombocytopenia are common to DIC, TTP,
and aHUS [2, 3], although patients with TTP and septic
DIC may have more severe thrombocytopenia [2, 12]. The
most important distinguishing factor between DIC and
TMAs is the coagulation profile, as patients with DICle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 An algorithm to rapidly differentiate disseminated intravascular coagulation (DIC) from thrombotic thrombocytopenic purpura (TTP) and
hemolytic uremic syndrome (HUS) in the intensive care unit (ICU). Thrombocytopenia with microangiopathic hemolytic anemia (MAHA), negative
Coombs test, elevated lactate dehydrogenase (LDH), and organ dysfunction are common to DIC, TTP, and HUS. Abnormal coagulation studies,
including prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen concentration, fibrin degradation products, D-dimers, and
antithrombin, are required for differentiation of DIC from thrombotic microangiopathies (TMAs). Additionally, blood pressure should be considered
because HUS usually presents with hypertension. Once DIC has been excluded, the underlying TMA must be identified. TTP is diagnosed by
identification of low ADAMTS13 activity (< 5-10%) and treated urgently with plasma exchange initially; HUS is associated with normal ADAMTS13 activity
(> 5–10%) and the type of HUS elucidated by performing a Shiga-toxin producing Escherichia coli (STEC) stool culture or polymerase chain reaction (PCR)
assay. Positive STEC strongly suggests STEC-HUS; negative STEC strongly suggests aHUS, with or without an associated complement-activating condition
(e.g., infection, malignant hypertension, the post-partum period, kidney transplantation, drugs, or malignancy). Rapid detection and management of any
associated complement-activating condition and consideration of eculizumab are required [3, 6, 9, 13]
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also important as HUS often presents with severe hyper-
tension and DIC with hypotension [3, 7]. The combined
evaluation of full blood count and blood smear, hemolysis
profile, coagulation profile, and blood pressure is usually
sufficient to ascertain whether a patient has DIC or a
TMA.
Once DIC has been excluded, confirming the cause of
the TMA is paramount for appropriate management.
The two most concerning causes of TMA are TTP andHUS. TTP is caused by a deficiency in a disintegrin-like
metalloproteinase with thrombospondin motif type 1
member 13 (ADAMTS13) and has 90% mortality with-
out plasma exchange [7]. HUS is caused by either Shiga
toxin (STEC-HUS) or complement dysregulation as a
result of genetic predisposition or autoantibodies (aHUS)
[3, 6, 7, 11]. An ADAMTS13 activity of < 5–10% is suffi-
cient to confirm TTP [3, 9] and a positive Shiga-toxin
stool culture or polymerase chain reaction (PCR) assay
confirms STEC-HUS [3, 9]. In the absence of low
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astating TMA, is highly likely [6]. Similar to DIC, aHUS
has a rapid onset and non-specific presentation [2, 3].
aHUS can be found in association with other
complement-activating states such as infection, malignant
hypertension, the post-partum period, kidney transplant-
ation, certain drugs, or malignancies [3]. There can be
substantial overlap in the presentation of these conditions
and they may coexist with complement-mediated aHUS,
making distinction difficult [3]. It should also be remem-
bered that aHUS can present with malignant hyperten-
sion, which itself can cause TMA [6, 9]. Rapid diagnosis
and treatment are essential to prevent irreversible organ
damage and death [13].
Like any pragmatic guidelines, we chose to focus on
the most common presentation as we considered this of
most benefit. For comprehensive guidance on TMA
diagnosis and management, we refer to other works,
such as those of Scully et al. [7], Campistol et al. [3],
Laurence et al. [9], and Azoulay et al. [11]. While the
proposed algorithm applies to the majority of cases of
thrombocytopenia, it must be noted that clinical judg-
ment and collaboration with experts is essential, as
exceptional clinical presentations do occur [14, 15].
It should also be noted that some of the tests required
in the differential diagnosis (e.g., ADAMTS13 activity
assay) are not available at all institutions. If rapid
ADAMTS13 testing is not possible, the PLASMIC score,
a seven-component prediction tool that can accurately
and reliably predict the probability of severe ADAMTS13
deficiency [10], can be used. Additionally, we have not
included genetic testing for the complement abnormalities
of aHUS in our algorithm; while these can confirm an
already suspected diagnosis of aHUS, the turnaround time
is currently considerable and should not be relied upon in
the ICU [11].
Critically ill patients have a range of clinical prob-
lems, including multi-organ failure, sepsis, and shock
[5], and early diagnosis and management are crucial
to optimize outcomes. We present a concise diagnos-
tic algorithm that enables intensivists to make a rapid
diagnosis so that they can initiate early appropriate
management for ICU patients with thrombocytopenia.
This algorithm adds to the current literature available
to the intensivist [11], with a focus on differentiating
TTP and HUS from DIC.Abbreviations
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